CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018
Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.
You may also be interested in...
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
The latest drug development news and highlights from our US FDA Performance Tracker.
New drugs approved in 2017 were not significantly different than those from years past in terms of innovative characteristics, but accelerated approval percentage took a sharp drop.
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.